AI platform for automated quantitative analysis of cell imaging
An AI-driven platform for automating quantitative analysis of brightfield cell images to enhance small molecule and peptide development. It offers automated cell detection, segmentation, and phenotyping, improving therapeutic efficacy and safety assessments.
Overview
Quantiscope PBC introduces an AI-driven platform designed to revolutionize the analysis of brightfield cell images for small molecule and peptide development. This innovative solution leverages advanced machine learning techniques to automate the quantification of therapeutic efficacy and safety. By processing high-content images of cells, the platform addresses the limitations of traditional phenotypic discovery methods through its ability to handle complex image data without human intervention.
Technical specifications
Key features:
- Automated cell detection and segmentation: Utilizes AI/ML tools to autonomously identify and segment cells in brightfield label-free images, akin to face detection technology.
- Enhanced cell phenotyping: Transforms cellular morphology and structure into quantitative data, providing insights into cellular functions and molecular activity.
- Scalability: Developed as a SaaS workflow that can be easily integrated into existing R&D pipelines, demonstrated by successful pilot testing with a leading pharmaceutical company.
Technology readiness level
The platform currently stands at TRL 5, indicating that it has been validated in a relevant environment. Ongoing development focuses on further automating the AI/ML models for cell detection and phenotyping, with plans to expand its capabilities to additional imaging modalities.
About Quantiscope PBC
Quantiscope PBC develops an AI-powered enterprise platform called phenotypIQ that automates biological quantification to support preclinical drug discovery and research. By applying machine learning and computer vision to microscopic images, the platform converts high-content biological imaging into actionable phenotypic data. This technology mirrors facial recognition methods, analyzing approximately 1,500 nodes of a cell to model cellular responses to various treatments, including small molecules, biologics, and genetic therapies. The cloud-based, plug-and-play solution is designed to integrate seamlessly into existing therapeutic pipelines, enabling researchers to conduct automated hit identification, enhance optimization, and improve decision-making regarding efficacy and toxicity.
The platform aims to streamline the drug development process, offering significant value to researchers by simplifying data interpretation and reducing the time required for clinical candidate selection. By democratizing access to advanced phenotypic modeling, Quantiscope supports diverse applications ranging from rare disease research to pandemic responsiveness and biodefense. Founded in 2022 and incubated at Altitude Lab, the company has engaged in pilot studies with various biotech and pharmaceutical partners, utilizing its SaaS-based tools to de-risk development and drive innovations in life sciences and biomanufacturing.
Inquire about this partnering listing
Industry applications
delivered to your inbox.